Virax Biolabs Group Limited, a biotechnology company, focuses on immune response detection, T cell immune profiling, and the development of in vitro diagnostic technologies for viral and immune-mediated diseases in the United Kingdom, the United States, and China. The company offers ViraxImmune, a T cell-based immune p…
| Métrica | VRAX | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | -838.2% | 57.4% | -895.6% |
| Operating Margin | -97344.8% | -34.4% | -97310.4% |
| Net Margin | -95739.2% | -32.5% | -95706.7% |
| FCF Margin | -81621.6% | -12.6% | -81609.1% |
| ROE | -106.4% | -39.2% | -67.2% |
| ROA | -94.3% | -30.9% | -63.4% |
| Current Ratio | 7.27 | 2.73 | +4.54 |
| Debt / Equity | — | 0.28 | — |
| Tendencia (Piotroski) | FY25 | FY24 |
|---|---|---|
| ✗Rentabilidad sobre activos positiva | -94.3% | — |
| ✗Flujo de caja operativo positivo | −$5M | — |
| –Rentabilidad sobre activos al alza | -94.3% | — |
| ✓Caja operativa/activos supera al ROA | -71.0% | ROA -94.3% |
| –Menos deuda a largo plazo | — | — |
| ✗Mejor liquidez (ratio corriente) | 7.27 | — |
| ✗Sin aumentar el nº de acciones | 4M | — |
| –Margen bruto al alza | -838.2% | — |
| –Rotación de activos al alza | 0.00 | — |
| Calidad del negocio | FY25 |
|---|---|
| ✗Margen FCF > 10 % | -81621.6% |
| ✗ROCE > 10 % | -107.1% |
| ✓Reinversión (I+D + capex) > 3 % de ventas | 37651.1% |
Virax Biolabs Group Ltd cotiza a 1.45 USD y tiene una capitalización bursátil de $2M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud